… that erlotinib would be efficacious in the adjuvant setting. … Adjuvant erlotinib did not improve
DFS in patients with EGFR … patients might benefit from adjuvant erlotinib was based on data …

… In this open-label phase II trial, patients with resected stage IA to IIIA (7 th edition of the …
Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (…

… therapy in patients with completely resected stage IB–IIIA NSCLC. However, gefitinib did
not show superiority over placebo in terms of either disease-free or overall survival. One …

… Moreover, the superiority of erlotinib over chemotherapy … erlotinib versus 20% with
chemotherapy. Recently, a phase 3 Chinese trial (ADJUVANT) that enrolled patients with stage …

… ) as an adjuvant treatment for stage IB-IIIA NSCLC. The … gefitinib as adjuvant chemotherapy
for EGFR-positive stage IIIA-… adjuvant treatment after curative resection of stage IIIA NSCLC, …

… Pts with completely resected IB-IIIA NSCLC were randomized 2:1 to receive E 150 mg qd
or P for 2 years. Pts were stratified according to stage, histology, prior adjuvant chemotherapy, …

… (23.4% v 23.7% with chemotherapy) trials,12 erlotinib … of adjuvant erlotinib for patients
with resected stage IA-IIIA EGFR1 … stages, especially those with stage IB, need to be clarified. …

… showed that adjuvant erlotinib improved both DFS and OS in patients with EGFR-mutant
stage IIIA NSCLC compared with chemotherapy [15]. Thus, whether adjuvant therapy with EGFR…

… adjuvant setting, showed remarkable preliminary DFS improvement in patients with stage
IB-IIIA … for comparing erlotinib with GC as neoadjuvant/adjuvant therapy in patients with stage …

… in stage IIIA. … IIIA disease and approximately 4% for patients with stage IB NSCLC. For stage
IA disease, despite the unacceptably high recurrence rate at 5 years, treatment with adjuvant …